2,463 Shares in Thermo Fisher Scientific Inc. $TMO Purchased by Alpine Woods Capital Investors LLC

Key Points

• Alpine Woods Capital Investors purchased 2,463 Thermo Fisher Scientific shares worth approximately $1.24 million, while institutional investors collectively own 89.23% of the company.
• Thermo Fisher reported quarterly revenue of $11.99 billion and adjusted earnings of $6.03 per share, exceeding analysts’ estimates; revenue increased 10.5% year over year.
• Analysts maintain a generally positive outlook, with a consensus “Moderate Buy” rating and a $619.41 target price. The company also declared a quarterly dividend of $0.47 per share, yielding about 0.3%.

Alpine Woods Capital Investors LLC purchased a new position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund purchased 2,463 shares of the medical research company's stock, valued at approximately $1,235,000.

Several other large investors have also bought and sold shares of TMO. Legacy Wealth Managment LLC ID grew its holdings in Thermo Fisher Scientific by 78.6% during the 1st quarter. Legacy Wealth Managment LLC ID now owns 50 shares of the medical research company's stock worth $25,000 after acquiring an additional 22 shares during the period. Allied Private Wealth LLC acquired a new position in shares of Thermo Fisher Scientific in the 2nd quarter valued at $26,000. High Note Wealth LLC grew its stake in shares of Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company's stock worth $27,000 after purchasing an additional 29 shares during the period. Swiss RE Ltd. bought a new stake in Thermo Fisher Scientific in the fourth quarter valued at about $28,000. Finally, JPL Wealth Management LLC acquired a new position in Thermo Fisher Scientific in the third quarter valued at about $28,000. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CAO Joseph R. Holmes sold 420 shares of the business's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $584.81, for a total value of $245,620.20. Following the sale, the chief accounting officer owned 2,966 shares of the company's stock, valued at $1,734,546.46. The trade was a 12.40% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Marc N. Casper sold 4,608 shares of the firm's stock in a transaction on Friday, August 7th. The shares were sold at an average price of $586.12, for a total transaction of $2,700,840.96. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 52,053 shares of company stock valued at $30,643,589 over the last 90 days. 0.33% of the stock is currently owned by company insiders.

Analyst Ratings Changes

Several equities analysts have recently issued reports on TMO shares. Sanford C. Bernstein assumed coverage on Thermo Fisher Scientific in a research report on Friday, June 26th. They set a "market perform" rating and a $520.00 target price for the company. Wall Street Zen upgraded shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a report on Saturday, August 1st. Evercore set a $570.00 price objective on Thermo Fisher Scientific in a report on Monday, July 6th. Jefferies Financial Group reissued a "buy" rating and set a $630.00 target price on shares of Thermo Fisher Scientific in a research note on Thursday, July 23rd. Finally, Wolfe Research assumed coverage on shares of Thermo Fisher Scientific in a research note on Tuesday, June 2nd. They issued an "outperform" rating and a $535.00 price target on the stock. One equities research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $619.41.

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $614.32 on Thursday. The company has a debt-to-equity ratio of 0.74, a current ratio of 1.55 and a quick ratio of 1.18. The firm has a market cap of $227.14 billion, a price-to-earnings ratio of 33.05, a price-to-earnings-growth ratio of 2.40 and a beta of 0.85. The stock's 50-day moving average is $536.26 and its 200-day moving average is $508.51. Thermo Fisher Scientific Inc. has a one year low of $435.27 and a one year high of $643.99.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings data on Thursday, July 23rd. The medical research company reported $6.03 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.71 by $0.32. Thermo Fisher Scientific had a return on equity of 17.09% and a net margin of 15.04%.The business had revenue of $11.99 billion during the quarter, compared to the consensus estimate of $11.71 billion. During the same period last year, the company earned $4.28 earnings per share. Thermo Fisher Scientific's quarterly revenue was up 10.5% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2026 guidance at 24.930-25.330 EPS. Equities analysts predict that Thermo Fisher Scientific Inc. will post 25.12 earnings per share for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Tuesday, September 15th will be paid a dividend of $0.47 per share. This represents a $1.88 annualized dividend and a dividend yield of 0.3%. The ex-dividend date of this dividend is Tuesday, September 15th. Thermo Fisher Scientific's dividend payout ratio (DPR) is currently 10.11%.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source